



DIAGNOSTIC AND PRONOSTIC OF TUMORAL HEMATOPATHOLOGIES

KEYWORDS

Myelodysplastic syndrome
Chronic myeloid leukemia
In vitro diagnostic
Genetic testing
Personalized medicine

CONTEXT

Myelodysplastic syndrome (MDS) is a disease of bone marrow characterized by low production of mature blood healthy cells. MDS can evolve toward acute myeloid leukemia (AML). Another severe haemopathy is chronic myeloid leukemia.

These blood diseases are characterized by a large and constant production of abnormal white blood cells..

87000 people worldwide are diagnosed each year with MDS.

Worldwide CML incidence range is between 1 and 1,75% .

TECHNOLOGY

The qPCR-based technology follows the expression of **genes involved in oxydative stress** which provides a specific pattern called « **Antioxydogram** ».

The technology displays two different applications:

- a MDS diagnostic kit able to improve classification of myelodysplastic syndromes, and to predict the transition to a worse pathologic stage.
- a CML prognostic kit to help in decision making for the appropriate treatment : technology provides information used by clinicians to better predict treatment response and to prescribe a 2nd generation of Tyrosine Kinase Inhibitors (TKI) to patients that are non-responder to imatinib (1st generation TKI).

ADVANTAGES

- Molecular longitudinal monitoring of myelodysplastic patients.
- Help in decision making to choose the best treatment for CML patients.
- Add-on to current diagnostic methods based on histology.
- Easy to set-up in a clinical environment.

INTELLECTUAL PROPERTY

Family of two patent applications:

- Patent N°1 : PCT in 2011, granted in USA, Japan and in progress in Europe
- Patent N°2 : PCT in 2015.

PARTNERSHIP

Available for codevelopment
and/or licensing out

RESEARCH TEAM

François Rabelais University
Tours, FRANCE

CNRS UMR 7292 – GICC
Team LNOx

Pr Olivier HERAULT

SATT GRAND CENTRE

is a French tech transfer
company having exclusive rights
to license out technologies
coming out of universities and
public research organizations
in France.

CONTACT

Magali **GRANGER**
Business Developer

+33 (0)6 34 22 36 89
magali.granger@sattgc.com

Headquarter:
8, rue Pablo PICASSO
FR63000 CLERMONT-FERRAND

www.sattgc.com